- Home
- ARBE vs UNCY Comparison
ARBE vs UNCY Comparison
Compare ARBE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARBE | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.0M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARBE | UNCY |
|---|---|---|
| Price | $1.12 | $6.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.63 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 5.8M | 669.8K |
| Earning Date | 02-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $667,000.00 | N/A |
| Revenue This Year | $69.79 | N/A |
| Revenue Next Year | $576.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $3.71 |
| 52 Week High | $2.91 | $11.00 |
Technical Indicators
Market Signals| Indicator | ARBE | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 46.41 |
| Support Level | $1.06 | $5.98 |
| Resistance Level | $1.21 | $6.78 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 14.00 | 19.86 |
Price Performance
Historical ComparisonAbout ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.